Viking Therapeutics (VKTX) announces positive top-line results from phase 2 venture-oral dosing trial of VK2735 tablet formulation in patients with obesity; Study achieves endpoints with significant weight reduction using VK2735

• Reports patients saw up to 12.2% mean weight loss with vk2735 after 13 weeks.


• VK2735 shown to be safe and well-tolerated in 13-week study.


• "Overall treatment discontinuation rates were 18% among placebo subjects compared with 28% among VK2735 subjects."

Reaction details (12:17)

• VKTX initially +31% in pre-market trade. However, move has since reversed, now 20% lower. 

Analysis details (12:13)

• Note, Eli Lilly's (LLY) weight loss pill (Orforglipron, Phase 3 ATTAIN-1 trial) saw orforglipron lower weight by an average of 12.4% at 72-weeks.


• The P3 Eli Lilly (LLY) trial saw an overall treatment discontinuation rates were 21.9% (6 mg), 22.5% (12 mg) and 24.4% (36 mg) for orforglipron vs. 29.9% with placebo.


• Stat News Adam Feuerstein posts on X citing Mizuho's Jared Holz, "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range but over 72-weeks. A much longer trial and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term. Pipeline and/or better versions needed to get investors and patients more interested. LLY could bounce a bit early but oral weight-loss programs continue to be highly controversial in terms of how they are perceived by the Street."

19 Aug 2025 - 12:09- EquitiesImportant- Source: Newswires